Psilocybin Shows Promise in Reducing OCD Symptoms in Early Trial

Bottom line: A Phase 1 trial suggests psilocybin may be associated with reduced OCD symptoms, but results are not yet public and further research is needed.

A new study is investigating whether a single dose of psilocybin — the active compound in certain mushrooms — could help reduce symptoms of obsessive-compulsive disorder (OCD). This is among the first controlled trials to explore its potential in a clinical setting.

What’s being tested

The trial is testing a single oral dose of psilocybin at 0.25mg/kg, along with 250mg of niacin. The researchers are looking to see if this combination can have an effect on OCD symptoms, which often include intrusive thoughts and repetitive behaviors that can significantly disrupt daily life.

The design at a glance

This is a Phase 1, double-blind, placebo-controlled study led by Yale University. Phase 1 trials are typically focused on safety, how the body processes the drug, and early signs of effectiveness. The study is now complete — data collection and analysis are done — but results have not been made public yet. In a double-blind trial, neither participants nor researchers know who received the drug or the placebo, which helps keep the study free from bias.

Why it matters

If psilocybin proves effective, it could offer a new option for people who haven’t responded to existing treatments. OCD can be difficult to treat, and current medications often come with side effects. A treatment that is both effective and well-tolerated could lead to better outcomes. Additionally, understanding how psilocybin might work in the brain could help scientists better understand the role of psychedelics in mental health overall.

What this does NOT mean yet

The trial is complete, but the results are not public. Just because a trial finishes doesn’t mean the treatment worked or was safe. The findings need to be peer-reviewed and published before they can be trusted. Phase 1 trials focus on safety and early clues about effectiveness, not long-term results or comparisons with other treatments. So while this is a step forward, it doesn’t prove psilocybin is a good option for OCD.

How to follow it

For updates, check the ClinicalTrials.gov record at NCT03356483. Results will be posted there once available. Often, trial results are also published in scientific journals, so following those could be the best way to track progress.

Sources

ClinicalTrials.gov (NCT03356483)

Educational Disclaimer

This article is for informational and educational purposes only. It is not medical advice, mental health advice, diagnosis, treatment guidance, or a recommendation to use any substance, supplement, therapy, or protocol.

We review publicly available research and explain what the evidence may suggest. Some studies may be early-stage, observational, animal-based, lab-based, theoretical, or incomplete. Always consult a qualified professional before making health-related decisions.

Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.

If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.